دورية أكاديمية
أعرض في EDS

The effects of various therapies on vulvovaginal atrophy and quality of life in gynecological cancer patients: a systematic review.

التفاصيل البيبلوغرافية
العنوان: The effects of various therapies on vulvovaginal atrophy and quality of life in gynecological cancer patients: a systematic review.
المؤلفون: Medeiros AG; Department of General Pathology, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, Uberaba, Minas Gerais, 38025-015, Brazil., Cintra MMM; Department of General Pathology, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, Uberaba, Minas Gerais, 38025-015, Brazil., Dos Reis MA; Department of General Pathology, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, Uberaba, Minas Gerais, 38025-015, Brazil., Rocha LP; Department of General Pathology, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, Uberaba, Minas Gerais, 38025-015, Brazil., do Carmo Neto JR; Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, GO, 74605-450, Brazil., Machado JR; Department of General Pathology, Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, Uberaba, Minas Gerais, 38025-015, Brazil. juliana.patologiageral@gmail.com.
المصدر: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2024 Aug; Vol. 310 (2), pp. 631-641. Date of Electronic Publication: 2024 Jun 19.
نوع المنشور: Systematic Review; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8710213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0711 (Electronic) Linking ISSN: 09320067 NLM ISO Abbreviation: Arch Gynecol Obstet Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: München : Springer International, c1987-
مواضيع طبية MeSH: Quality of Life* , Atrophy* , Genital Neoplasms, Female*/therapy , Genital Neoplasms, Female*/psychology , Genital Neoplasms, Female*/pathology , Vagina*/pathology , Vulva*/pathology, Humans ; Female ; Vaginal Diseases/therapy ; Vaginal Diseases/pathology ; Lasers, Gas/therapeutic use ; Suppositories ; Administration, Intravaginal
مستخلص: Purpose: Tumors affecting the female genital tract and their treatments have the potential to induce adverse modifications in vaginal health and impact personal aspects of patient's lives. Vulvovaginal atrophy is one of the morphological changes observed in individuals with a history of gynecological cancer, influenced both by the biological environment of tumors and the main therapeutic modalities employed. Therefore, the purpose of this study was to identify approaches to treat vulvovaginal atrophy while assessing the impact on the emotional and sexual health of women diagnosed with gynecological cancers.
Methods: To achieve this goal, a systematic review was conducted following the methodological guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The databases used for literature research were PubMed and Web of Science.
Results: Initially, 886 articles were obtained. After eliminating duplicates and applying inclusion/exclusion criteria, seven articles were selected for analysis. The period of highest publication activity spanned from 2017 to 2020, with the majority conducted in Italy. Five treatment modalities were identified and categorized as vaginal suppository, oral medication, surgical procedure, CO2 laser therapy, and vaginal dilator. Twenty-four outcomes related to vaginal health and 30 outcomes related to overall, sexual, and emotional quality of life were analyzed.
Conclusion: In general, all interventions demonstrated the ability to improve vaginal health or, at the very least, the sexual health of patients. Thus, despite limitations, all treatments have the potential to address vulvovaginal atrophy in patients with a history of gynecological cancer.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA (2016) Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 215:704–711. https://doi.org/10.1016/j.ajog.2016.07.045. (PMID: 10.1016/j.ajog.2016.07.04527472999)
Carter J, Stabile C, Seidel B, Baser RE, Goldfarb S, Goldfrank DJ (2017) Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. J Cancer Surviv 11:274–283. https://doi.org/10.1007/s11764-016-0585-9. (PMID: 10.1007/s11764-016-0585-927868156)
Cook ED, Iglehart EI, Baum G, Schover LL, Newman LL (2017) Missing documentation in breast cancer survivors: genitourinary syndrome of menopause. Menopause 24:1360–1364. https://doi.org/10.1097/GME.0000000000000926. (PMID: 10.1097/GME.0000000000000926286401665709152)
DeSimone M, Spriggs E, Gass JS, Carson SA, Krychman ML, Dizon DS (2014) Sexual dysfunction in female cancer survivors. Am J Clin Oncol. 37:101–106. https://doi.org/10.1097/COC.0b013e318248d89d. (PMID: 10.1097/COC.0b013e318248d89d22643563)
Burich R, Degregorio M (2014) Current treatment options for vulvovaginal atrophy. Expert Rev Obstet Gynecol 6:141–151. https://doi.org/10.1586/EOG.11.3. (PMID: 10.1586/EOG.11.3)
Erekson EA, Li FY, Martin DK, Fried TR (2016) Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. Menopause 23:368–375. https://doi.org/10.1097/GME.0000000000000549. (PMID: 10.1097/GME.0000000000000549266458204814326)
Nappi RE, Palacios S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 17:3–9. https://doi.org/10.3109/13697137.2013.871696. (PMID: 10.3109/13697137.2013.87169624423885)
Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M, Society of Gynecologic Surgeons Systematic Review Group (2014) Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 124:1147–1156. https://doi.org/10.1097/AOG.0000000000000526. (PMID: 10.1097/AOG.0000000000000526254151664855283)
Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11:96–110. https://doi.org/10.1634/theoncologist.11-2-96. (PMID: 10.1634/theoncologist.11-2-9616476831)
Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, Suárez-Almarza J, Velasco-Ortega S, Nieto C (2018) Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric 21(2):167–173. https://doi.org/10.1080/13697137.2017.1421921. (PMID: 10.1080/13697137.2017.142192129411644)
Jensen PT, Froeding LP (2015) Pelvic radiotherapy and sexual function in women. Transl Androl Urol 4:186–205. https://doi.org/10.3978/j.issn.2223-4683.2015.04.06. (PMID: 10.3978/j.issn.2223-4683.2015.04.06268168244708128)
Del Carmen MG, Rice LW (2017) Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol. 146:427–435. https://doi.org/10.1016/j.ygyno.2017.06.013. (PMID: 10.1016/j.ygyno.2017.06.01328625396)
Kapoor S, Sivanesan K, Robertson JA, Veerasingham M, Kapoor V (2017) Sacrospinous hysteropexy: review and meta-analysis of outcomes. Int Urogynecol J 28:1285–1294. https://doi.org/10.1007/s00192-017-3291-x. (PMID: 10.1007/s00192-017-3291-x28258346)
Portman D, Palacios S, Nappi RE, Mueck AO (2014) Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 78:91–98. https://doi.org/10.1016/j.maturitas.2014.02.015. (PMID: 10.1016/j.maturitas.2014.02.01524679891)
Salvatore S, Athanasiou S, Candiani M (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27:504–508. https://doi.org/10.1097/GCO.0000000000000230 . Erratum in: Curr Opin Obstet Gynecol 2017, 29:282.
De Rosa N, Lavitola G, Giampaolino P, Morra I, Nappi C, Bifulco G (2017) Impact of Ospemifene on quality of life and sexual function in young survivors of cervical cancer: a prospective study. Biomed Res Int 2017:7513610. https://doi.org/10.1155/2017/7513610. (PMID: 10.1155/2017/7513610287819685525090)
Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B (2020) Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol 157:303–306. https://doi.org/10.1016/j.ygyno.2020.01.035. (PMID: 10.1016/j.ygyno.2020.01.03532067815)
Biglia N, Bounous VE, D’Alonzo M, Ottino L, Tuninetti V, Robba E, Perrone T (2017) Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer 17:611–617. https://doi.org/10.1016/j.clbc.2017.05.008. (PMID: 10.1016/j.clbc.2017.05.00828655486)
Galvao TF, Pansani TSA, Harrad D (2015) Principais itens para relatar Revisoes sistemáticas e Meta-análises: a recomendacao Prisma. Epidemiologia e Servicos de Saúde 24:335–342. https://doi.org/10.5123/S1679-49742015000200017. (PMID: 10.5123/S1679-49742015000200017)
McGowan JM, Sampson DM, Salzwedel E, Cogo V (2016) Foerster, and C. Lefebvre, “PRESS Peer Review of ElectronicSearch Strategies: 2015 Guideline Statement,” Journal of Clin-ical Epidemiology, vol. 75, pp. 40–46 (PDF) Neuroprotective Treatments for Digestive Forms of Chagas Disease in Experimental Models: a Systematic Review. Available from: https://www.researchgate.net/publication/363856599_Neuroprotective_Treatments_for_Digestive_Forms_of_Chagas_Disease_in_Experimental_Models_A_Systematic_Review [accessed Nov 23 2023].
Angioli R, Stefano S, Filippini M, Pieralli A, Montera R, Plotti F, Gatti A, Bartolone M, Luvero D (2020) Effectiveness of CO2 laser on urogenital syndrome in women with a previous gynecological neoplasia: a multicentric study. Int J Gynecol Cancer 30:590–595. https://doi.org/10.1136/ijgc-2019-001028. (PMID: 10.1136/ijgc-2019-00102832221022)
Perrone AM, Tesei M, Ferioli M, De Terlizzi F, Della Gatta AN, Boussedra S, Dondi G, Galuppi A, Morganti AG, De Iaco P (2020) Results of a phase I–II study on laser therapy for vaginal side effects after radiotherapy for cancer of uterine cervix or endometrium. Cancers (Basel) 12:1639. https://doi.org/10.3390/cancers12061639. (PMID: 10.3390/cancers1206163932575821)
Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M (2020) Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 144:37–44. https://doi.org/10.1016/j.maturitas.2020.10.018. (PMID: 10.1016/j.maturitas.2020.10.018333582067773136)
Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC (2019) Vaginal Health in Menopausal Women. Medicina (Kaunas) 55:615. https://doi.org/10.3390/medicina55100615. (PMID: 10.3390/medicina5510061531547180)
Miles T, Johnson N (2014) Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2014:CD007291. https://doi.org/10.1002/14651858.CD007291.pub3. (PMID: 10.1002/14651858.CD007291.pub3251981506513398)
Minkin MJ, Maamari R, Reiter S (2013) Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health 5:133–139. https://doi.org/10.2147/IJWH.S41897. (PMID: 10.2147/IJWH.S41897235261713604875)
Paraiso MFR, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, Iglesia CB (2020) A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Menopause. 27:50–56. https://doi.org/10.1097/GME.0000000000001416. (PMID: 10.1097/GME.000000000000141631574047)
Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, Wajsfeld T, Fernandes CE (2018) Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 25:21–28. https://doi.org/10.1097/GME.0000000000000955. (PMID: 10.1097/GME.000000000000095528763401)
Gaspar A, Brandi H, Gomez V, Luque D (2017) Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med 49:160–168. https://doi.org/10.1002/lsm.22569. (PMID: 10.1002/lsm.2256927546524)
Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF (2019) Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause 26(8):833–840. https://doi.org/10.1097/GME.0000000000001333. (PMID: 10.1097/GME.000000000000133331246661)
Benini V, Ruffolo AF, Casiraghi A, Degliuomini RS, Frigerio M, Braga A, Serati M, Torella M, Candiani M, Salvatore S (2022) New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas) 58:770. https://doi.org/10.3390/medicina58060770. (PMID: 10.3390/medicina5806077035744033)
Gambacciani M, Palacios S (2017) Laser therapy for the restoration of vaginal function. Maturitas 99:10–15. https://doi.org/10.1016/j.maturitas.2017.01.012. (PMID: 10.1016/j.maturitas.2017.01.01228364861)
Dinicola S, Pasta V, Costantino D, Guaraldi C, Bizzarri M (2015) Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy. Minerva Ginecol 67:523–531. (PMID: 26788875)
De Seta F, Caruso S, Di Lorenzo G, Romano F, Mirandola M, Nappi RE (2021) Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: a double-blind randomized placebo-controlled study. Maturitas 147:34–40. https://doi.org/10.1016/j.maturitas.2021.03.002. (PMID: 10.1016/j.maturitas.2021.03.00233832645)
Nappi RE, Kotek M, Brešt’anský A, Giordan N, Tramentozzi E (2020) Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. Climacteric 23:519–524. https://doi.org/10.1080/13697137.2020.1754386. (PMID: 10.1080/13697137.2020.175438632396754)
Gold D, Nicolay L, Avian A, Greimel E, Balic M, Pristauz-Telsnigg G, Tamussino K, Trutnovsky G (2023) Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. Maturitas 167:1–7. https://doi.org/10.1016/j.maturitas.2022.08.013. (PMID: 10.1016/j.maturitas.2022.08.01336279690)
Hersant B, SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP (2018) Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause 25:1124–1130. https://doi.org/10.1097/GME.0000000000001122. (PMID: 10.1097/GME.000000000000112229738415)
Buzzaccarini G, Marin L, Noventa M, Vitagliano A, Riva A, Dessole F, Capobianco G, Bordin L, Andrisani A, Ambrosini G (2021) Hyaluronic acid in vulvar and vaginal administration: evidence from a literature systematic review. Climacteric 24:560–571. https://doi.org/10.1080/13697137.2021.1898580. (PMID: 10.1080/13697137.2021.189858033759670)
Palacios S (2020) Ospemifene for vulvar and vaginal atrophy: an overview. Drugs Context 9:1–5. https://doi.org/10.7573/dic.2020-3-2. (PMID: 10.7573/dic.2020-3-2)
Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O, Ospemifene Study Group (2014) Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 17:173–182. https://doi.org/10.3109/13697137.2013.834493. (PMID: 10.3109/13697137.2013.83449323984673)
Alvisi S, Baldassarre M, Gava G, Mancini I, Gagliardi M, Seracchioli R, Meriggiola MC (2018) Structure of epithelial and stromal compartments of vulvar and vaginal tissue from women with vulvo-vaginal atrophy taking ospemifene. J Sex Med 15:1776–1784. https://doi.org/10.1016/j.jsxm.2018.10.009. (PMID: 10.1016/j.jsxm.2018.10.00930446472)
Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA (2015) Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 18:226–232. https://doi.org/10.3109/13697137.2014.954996. (PMID: 10.3109/13697137.2014.95499625252699)
Schiavi MC, Sciuga V, Giannini A, Vena F, D’oria O, Prata G, Di Tucci C, Savone D, Aleksa N, Capone C, Di Mascio D, Meggiorini ML, Monti M, Zullo MA, Muzii L, Benedetti Panici P (2018) Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 34(8):666–669. https://doi.org/10.1080/09513590.2018.1441398. (PMID: 10.1080/09513590.2018.144139829463148)
Seror J, Roulot A, Guillot E, Rouzier R (2017) Colpoplasty by laparoscopic modified Davydov’s procedure. Gynecol Oncol 144(3):647–648. https://doi.org/10.1016/j.ygyno.2017.01.004. (PMID: 10.1016/j.ygyno.2017.01.00428081882)
Davydov SN, Zhvitiashvili OD (1974) Formation of vagina (colpopoiesis) from peritoneum of Douglas pouch. Acta Chir Plast 16:35–41. (PMID: 4141200)
Quinn BA, Deng X, Sullivan SA, Carter J, Bandyopadhyay D, Fields EC (2023) Change in vaginal length and sexual function in women who undergo surgery ± radiation therapy for endometrial cancer. Brachytherapy 22:334–342. https://doi.org/10.1016/j.brachy.2023.01.005. (PMID: 10.1016/j.brachy.2023.01.00536849277)
Bahng AY, Dagan A, Bruner DW, Lin LL (2012) Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. Int J Radiat Oncol Biol Phys 82:667–673. https://doi.org/10.1016/j.ijrobp.2010.10.071. (PMID: 10.1016/j.ijrobp.2010.10.07121300451)
Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP, Straub M, Bradley KA (2012) Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys 84:973–982. https://doi.org/10.1016/j.ijrobp.2012.01.064. (PMID: 10.1016/j.ijrobp.2012.01.064228983813706199)
Law E, Kelvin JF, Thom B, Riedel E, Tom A, Carter J, Alektiar KM, Goodman KA (2015) Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiother Oncol 116:149–155. https://doi.org/10.1016/j.radonc.2015.06.018. (PMID: 10.1016/j.radonc.2015.06.018261647755028178)
فهرسة مساهمة: Keywords: Gynecological cancer; Sexual health; Systematic review; Treatments; Vaginal atrophy; Vaginal health
المشرفين على المادة: 0 (Suppositories)
تواريخ الأحداث: Date Created: 20240619 Date Completed: 20240718 Latest Revision: 20240719
رمز التحديث: 20240719
DOI: 10.1007/s00404-024-07552-9
PMID: 38898186
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0711
DOI:10.1007/s00404-024-07552-9